Skip to main content
TipRanks
Go Ultimate75% OFF

Biovica International AB Class B (9II) AI Stock Analysis

1 Followers
DE:9II

Biovica International AB Class B

(Frankfurt:9II)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthRising revenue indicates improving commercial traction for Biovica’s oncology diagnostics offering. If this growth persists, greater test adoption can improve operating leverage, support broader market penetration, and provide a foundation for eventual profitability.
Negative Factors
Persistent UnprofitabilityNegative gross profit shows that current revenue does not yet cover the direct economics of the business, before broader operating expenses. This limits internal capital generation, keeps break-even uncertain, and makes durable profitability dependent on substantial improvement in commercial economics.

Biovica International AB Class B (9II) vs. iShares MSCI Germany ETF (EWG)

-75%-50%-25%0%25%50%75%100%DE:9II-23.81%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 7.72M
Dividend Yield
―
Average Volume (3M)
20.00K
Price to Earnings (P/E)
-1.2
Beta (1Y)
8.64
Revenue Growth
61.35%
EPS Growth
62.60%
Country
Germany
Employees
24
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Biovica International AB Class B Business Overview & Revenue Model

Company Description

Biovica International AB (publ) operates as a biotechnology enterprise, concentrating on the development and market introduction of sophisticated blood-based biomarker tests. These diagnostic solutions aim to enhance the tracking and prediction of ca...

Biovica International AB Class B Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:9II against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA83OutperformSEK 360.89M1.9063.09%―――
SE:SPRINTSE:SPRINT80OutperformSEK 400.96M5.4971.44%―170.38%―
SE:FLUISE:FLUI70OutperformSEK 29.81M5.8434.47%―630.57%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ELICSE:ELIC48NeutralSEK 162.84M-6.97-56.09%――14.10%
SE:SPAGOSE:SPAGO42NeutralSEK 33.21M-1.03-87.37%―-97.52%31.31%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%400%DE:9IISE:ELICSE:SPAGOSE:CANTASE:SPRINTSE:FLUIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:9II and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:9IIBiovica International AB Class B0.02-0.00-11.11%
SE:ELICElicera Therapeutics AB2.46-2.70-52.27%
SE:SPAGOSpago Nanomedical AB0.04-0.05-56.84%
SE:CANTACantargia AB1.29-1.94-60.03%
SE:SPRINTSprint Bioscience AB3.682.24155.56%
SE:FLUIFluicell AB21.1010.3095.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.